Stoke Therapeutics, Inc. (STOK) Reports Q3 Loss, Beats Revenue Estimates

Core Insights - Stoke Therapeutics reported a quarterly loss of $0.65 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.54, marking a year-over-year increase from a loss of $0.47 per share [1] - The company achieved revenues of $10.63 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 69.03% and showing significant growth from $4.89 million in the same quarter last year [2] - Stoke Therapeutics shares have increased approximately 136.6% year-to-date, significantly outperforming the S&P 500's gain of 16.5% [3] Earnings Outlook - The future performance of Stoke Therapeutics' stock will largely depend on management's commentary during the earnings call and the company's earnings outlook [4] - The current consensus EPS estimate for the upcoming quarter is -$0.65 with projected revenues of $6.13 million, while the estimate for the current fiscal year is $0.28 on revenues of $183.79 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Stoke Therapeutics belongs, is currently ranked in the top 39% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8]